Endoscopic and clinical variables that predict sustained remission in children with ulcerative colitis treated with infliximab

Clicks: 616
ID: 265925
2013
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
On the basis of a post hoc analysis of data from the T72 clinical trial on the effect of infliximab in pediatric patients with UC, the PUCAI was no less predictive of sustained remission than mucosal healing at week 8, and both were superior to CRP level. Routine endoscopic evaluation in children wi …
Reference Key
d2013clinicalendoscopic Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Turner D;Griffiths AM;Veerman G;Johanns J;Damaraju L;Blank M;Hyams J;;
Journal clinical gastroenterology and hepatology : the official clinical practice journal of the american gastroenterological association
Year 2013
DOI
DOI not found
URL
https://www.pubmed.gov/23672831/
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine treatment outcome female male adolescent Child Clinical Trial Antibodies Monoclonal / therapeutic use* Multicenter Study Colitis Ulcerative / drug therapy* c-reactive protein / analysis infliximab intestinal mucosa / pathology immunologic factors / therapeutic use* pmid:23672831 doi:10.1016/j.cgh.2013.04.049 dan turner anne m griffiths jeffrey hyams ulcerative / pathology* colon / pathology* colonoscopy

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.